TXMD - TherapeuticsMD, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.20
+0.02 (+0.39%)
As of 2:21PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close5.18
Open5.14
Bid5.20 x 800
Ask5.21 x 1800
Day's Range5.14 - 5.28
52 Week Range3.51 - 7.66
Volume1,049,586
Avg. Volume3,282,084
Market Cap1.237B
Beta (3Y Monthly)2.31
PE Ratio (TTM)N/A
EPS (TTM)-0.52
Earnings DateNov 1, 2017 - Nov 6, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.00
Trade prices are not sourced from all markets
  • Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options
    Zacks6 hours ago

    Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options

    Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.

  • Markit6 hours ago

    See what the IHS Markit Score report has to say about TherapeuticsMD Inc.

    # TherapeuticsMD Inc ### NASDAQ/NGS:TXMD View full report here! ## Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is high ## Bearish sentiment Short interest | Negative Short interest is extremely high for TXMD with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TXMD. ## Money flow ETF/Index ownership | Negative ETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding TXMD totaled $172 million. Additionally, the rate of outflows appears to be accelerating. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Why TherapeuticsMD's Stock Spiked Today
    Motley Fool7 days ago

    Why TherapeuticsMD's Stock Spiked Today

    Traders are feeling giddy after management shared the bull case for owning its stock at an important investor conference.

  • Markit8 days ago

    See what the IHS Markit Score report has to say about TherapeuticsMD Inc.

    # TherapeuticsMD Inc ### NASDAQ/NGS:TXMD View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high ## Bearish sentiment Short interest | Negative Short interest is extremely high for TXMD with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TXMD. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding TXMD is favorable, with net inflows of $3.77 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wire14 days ago

    TherapeuticsMD Announces Participation at 37th Annual J.P. Morgan Healthcare Conference

    TherapeuticsMD, Inc. , an innovative women’s healthcare company, today announced that the company will participate in the 37th Annual J.P. Morgan Healthcare Conference.

  • TheStreet.com27 days ago

    The Charts of TherapeuticsMD Look Bearish to Me

    In this daily bar chart of TXMD, below, we can see that prices are in a downtrend from June. The daily On-Balance-Volume (OBV) line shows a decline which indicates more aggressive selling, even at these low price levels. In this weekly bar chart of TXMD, we also have a weak picture.

  • Benzinga27 days ago

    Jim Cramer Weighs In On Palo Alto, Blackstone And More

    On CNBC's "Mad Money Lightning Round" , Jim Cramer said Owens Corning (NYSE: OC ) is related to housing and it has been wrecked by the Fed. Mortgages rates went up too fast, said Cramer. Hormel ...

  • CNBC28 days ago

    Cramer's lightning round: These cybersecurity stocks are the ones to own in this market

    Jim Cramer races through his responses to callers' stock questions, including one on a group he's telling investors to buy right now.

  • Is TherapeuticsMD Inc (TXMD) A Good Stock To Buy?
    Insider Monkey28 days ago

    Is TherapeuticsMD Inc (TXMD) A Good Stock To Buy?

    Is TherapeuticsMD Inc (NASDAQ:TXMD) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more resources than the average investor. The funds have access to […]

  • See what the IHS Markit Score report has to say about TherapeuticsMD Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about TherapeuticsMD Inc.

    TherapeuticsMD Inc NASDAQ/NGS:TXMD

  • GlobeNewswirelast month

    Detailed Research: Economic Perspectives on TESARO, Regeneron Pharmaceuticals, Pool, Zebra Technologies, Cadence Design, and TherapeuticsMD — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Fast-growing pharmaceutical company signs $20M lease to expand Boca Raton HQ
    American City Business Journals2 months ago

    Fast-growing pharmaceutical company signs $20M lease to expand Boca Raton HQ

    TherapeuticsMD signed a 56,212-square-foot lease to replace its headquarters to a larger building in Boca Raton. The pharmaceutical company (Nasdaq: TXMD) will move into 951 Yamato Road. Jay M. Grossman and Richard W. Brockney of NAI/Merin Hunter Codman represented landlord Brookwood Financial Partners in the deal.

  • Business Wire2 months ago

    TherapeuticsMD Announces Participation in Three Upcoming Investor Conferences

    TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that the company will participate in three upcoming healthcare investor conferences. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conferences.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of TXMD earnings conference call or presentation 7-Nov-18 9:30pm GMT

    Q3 2018 TherapeuticsMD Inc Earnings Call

  • Associated Press2 months ago

    TherapeuticsMD: 3Q Earnings Snapshot

    The Boca Raton, Florida-based company said it had a loss of 16 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • Business Wire2 months ago

    TherapeuticsMD Announces Third Quarter 2018 Financial Results

    -Strong early launch indicators for IMVEXXY™-

  • Simply Wall St.2 months ago

    TherapeuticsMD Inc’s (NASDAQ:TXMD) Profit Outlook

    TherapeuticsMD Inc’s (NASDAQ:TXMD): TherapeuticsMD, Inc. operates as a women’s health care product company. With the latest financial year loss of -US$77m and a trailing-twelve month of -US$94m, the US$1.2b market-cap Read More...

  • Business Wire3 months ago

    TherapeuticsMD to Report Third Quarter 2018 Financial Results on November 7, 2018

    TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that it will report its third quarter 2018 financial results on Wednesday, November 7, 2018, after the closing of the U.S. financial markets.

  • Why TherapeuticsMD Is Sinking Despite Sharing Good News
    Motley Fool3 months ago

    Why TherapeuticsMD Is Sinking Despite Sharing Good News

    An FDA approval usually triggers a rally, so why are shares down today?

  • TherapeuticsMD (TXMD) Q3 Earnings Preview: What to Watch Ahead of the Release
    Zacks3 months ago

    TherapeuticsMD (TXMD) Q3 Earnings Preview: What to Watch Ahead of the Release

    TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • ACCESSWIRE3 months ago

    Today's Research Reports on Trending Tickers: TherapeuticsMD and Horizon Pharma Public

    NEW YORK, NY / ACCESSWIRE / October 29, 2018 / U.S. equities rolled back on Friday as disappointing corporate earnings added to the bearish sentiment in the market. The Dow Jones Industrial Average shed ...

  • Reuters3 months ago

    U.S. FDA approves TherapeuticsMD's menopause drug

    The U.S. Food and Drug Administration (FDA) approved TherapeuticsMD's oral hormone therapy for menopause symptoms such as hot flashes, sleep disturbances and night sweats, the company said on Monday. The regulatory nod is the third in five months for the drugmaker, which received approvals for a birth control device and another hormone therapy for menopause symptoms. The therapy, Bijuva, is an oral softgel capsule containing a combination of artificial hormones chemically identical to human female sex hormones estradiol and progesterone.

  • Business Wire3 months ago

    TherapeuticsMD Announces FDA Approval of TX-001HR: BIJUVA™ (Estradiol and Progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause

    TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that the United States Food and Drug Administration (FDA) has approved BIJUVA™ (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bio-identical* hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.

  • See what the IHS Markit Score report has to say about TherapeuticsMD Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about TherapeuticsMD Inc.

    Short interest is extremely high for TXMD with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TXMD. Over the last one-month, outflows of investor capital in ETFs holding TXMD totaled $431 million.

  • GlobeNewswire3 months ago

    Consolidated Research: 2018 Summary Expectations for Novavax, Caesars Entertainment, SeaWorld Entertainment, LendingTree, CVS Health, and TherapeuticsMD — Fundamental Analysis, Key Performance Indications

    NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.